IDEXX Laboratories Valuation
Is IDXX * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of IDXX * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: IDXX * (MX$9008.75) is trading above our estimate of fair value (MX$4078.14)
Significantly Below Fair Value: IDXX * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IDXX *?
Other financial metrics that can be useful for relative valuation.
| What is IDXX *'s n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$40.59b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 11.1x |
| Enterprise Value/EBITDA | 33.5x |
| PEG Ratio | 4.7x |
Price to Earnings Ratio vs Peers
How does IDXX *'s PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 39.9x | ||
GEHC GE HealthCare Technologies | 22.9x | 13.0% | US$36.0b |
EW Edwards Lifesciences | 38.8x | 9.9% | US$54.3b |
300760 Shenzhen Mindray Bio-Medical Electronics | 29.1x | 15.2% | CN¥354.6b |
DXCM DexCom | 68.6x | 18.2% | US$44.0b |
IDXX * IDEXX Laboratories | 46.8x | 9.9% | Mex$40.6b |
Price-To-Earnings vs Peers: IDXX * is expensive based on its Price-To-Earnings Ratio (46.8x) compared to the peer average (39.9x).
Price to Earnings Ratio vs Industry
How does IDXX *'s PE Ratio compare vs other companies in the Global Medical Equipment Industry?
Price-To-Earnings vs Industry: IDXX * is expensive based on its Price-To-Earnings Ratio (46.8x) compared to the Global Medical Equipment industry average (26x).
Price to Earnings Ratio vs Fair Ratio
What is IDXX *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 46.8x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate IDXX *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | Mex$9,008.75 | Mex$10,225.67 +13.5% | 12.0% | Mex$11,618.77 | Mex$7,250.40 | n/a | 11 |
| Jun ’25 | Mex$8,456.60 | Mex$9,496.39 +12.3% | 11.4% | Mex$10,796.75 | Mex$6,737.44 | n/a | 12 |
| May ’25 | Mex$8,605.03 | Mex$9,903.81 +15.1% | 13.0% | Mex$11,487.02 | Mex$6,807.12 | n/a | 13 |
| Apr ’25 | n/a | Mex$9,852.45 0% | 12.8% | Mex$11,352.42 | Mex$6,727.36 | n/a | 13 |
| Mar ’25 | n/a | Mex$9,953.74 0% | 13.3% | Mex$11,506.39 | Mex$6,818.60 | n/a | 12 |
| Feb ’25 | Mex$8,998.70 | Mex$9,495.44 +5.5% | 14.1% | Mex$11,200.67 | Mex$6,048.36 | n/a | 12 |
| Jan ’25 | Mex$9,463.45 | Mex$9,025.04 -4.6% | 13.6% | Mex$10,384.38 | Mex$6,074.86 | n/a | 12 |
| Dec ’24 | Mex$8,314.90 | Mex$8,783.42 +5.6% | 14.7% | Mex$10,319.64 | Mex$6,036.99 | n/a | 11 |
| Nov ’24 | Mex$7,154.79 | Mex$9,542.70 +33.4% | 14.5% | Mex$10,687.38 | Mex$6,252.12 | n/a | 11 |
| Oct ’24 | n/a | Mex$9,606.75 0% | 12.9% | Mex$10,271.10 | Mex$6,008.59 | n/a | 11 |
| Sep ’24 | Mex$8,568.55 | Mex$9,646.54 +12.6% | 12.8% | Mex$10,657.06 | Mex$5,985.01 | n/a | 11 |
| Aug ’24 | n/a | Mex$9,347.29 0% | 12.7% | Mex$10,116.78 | Mex$5,918.32 | n/a | 11 |
| Jul ’24 | n/a | Mex$9,505.86 0% | 13.1% | Mex$10,546.44 | Mex$6,169.67 | n/a | 10 |
| Jun ’24 | Mex$8,302.35 | Mex$9,505.86 +14.5% | 13.1% | Mex$10,546.44 | Mex$6,169.67 | Mex$8,456.60 | 10 |
| May ’24 | Mex$8,750.00 | Mex$9,703.88 +10.9% | 14.5% | Mex$10,858.50 | Mex$5,899.79 | Mex$8,605.03 | 10 |
| Apr ’24 | n/a | Mex$9,974.47 0% | 14.5% | Mex$11,171.70 | Mex$6,069.96 | n/a | 10 |
| Mar ’24 | n/a | Mex$9,902.03 0% | 14.9% | Mex$11,149.08 | Mex$6,057.67 | n/a | 9 |
| Feb ’24 | n/a | Mex$9,157.28 0% | 14.8% | Mex$10,923.67 | Mex$6,118.76 | Mex$8,998.70 | 9 |
| Jan ’24 | n/a | Mex$8,978.40 0% | 15.3% | Mex$11,275.20 | Mex$6,315.66 | Mex$9,463.45 | 9 |
| Dec ’23 | n/a | Mex$8,978.40 0% | 15.3% | Mex$11,275.20 | Mex$6,315.66 | Mex$8,314.90 | 9 |
| Nov ’23 | n/a | Mex$9,224.70 0% | 17.2% | Mex$11,606.77 | Mex$6,501.39 | Mex$7,154.79 | 9 |
| Oct ’23 | n/a | Mex$9,466.45 0% | 16.0% | Mex$11,550.26 | Mex$6,469.73 | n/a | 9 |
| Sep ’23 | Mex$6,915.00 | Mex$9,466.45 +36.9% | 16.0% | Mex$11,550.26 | Mex$6,469.73 | Mex$8,568.55 | 9 |
| Aug ’23 | n/a | Mex$10,217.96 0% | 22.7% | Mex$14,324.24 | Mex$6,671.00 | n/a | 9 |
| Jul ’23 | n/a | Mex$10,651.06 0% | 20.0% | Mex$14,021.14 | Mex$6,529.85 | n/a | 8 |
| Jun ’23 | Mex$7,560.00 | Mex$10,847.01 +43.5% | 19.6% | Mex$14,031.71 | Mex$6,534.77 | Mex$8,302.35 | 8 |
Analyst Forecast: Target price is less than 20% higher than the current share price.